Romidepsin targets multiple survival signaling pathways in malignant T cells

Romidepsin is a cyclic molecule that inhibits histone deacetylases. It is Food and Drug Administration-approved for treatment of cutaneous and peripheral T-cell lymphoma, but its precise mechanism of action against malignant T cells is unknown. To better understand the biological effects of romideps...

Descripción completa

Detalles Bibliográficos
Autores principales: Valdez, B C, Brammer, J E, Li, Y, Murray, D, Liu, Y, Hosing, C, Nieto, Y, Champlin, R E, Andersson, B S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635192/
https://www.ncbi.nlm.nih.gov/pubmed/26473529
http://dx.doi.org/10.1038/bcj.2015.83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635192/
https://www.ncbi.nlm.nih.gov/pubmed/26473529
http://dx.doi.org/10.1038/bcj.2015.83

Ejemplares similares